InterMed Discovery Announces Collaboration Agreement With the Lead Discovery Center
InterMed Discovery (IMD announced the start of a screening project for the lead discovery Center GmbH (LDC), a Max-Planck-Innovation company. The LDC was founded in 2008 in close proximity to IMD at the University Campus at Dortmund and forms an essential part of Max-Planck-Innovation's Drug Discovery & Development Center (DDC).
The objective of this collaboration project between IMD and the LDC is to identify naturally derived modulators by screening IMD’s natural product libraries against targets provided by LDC and based on intellectual property previously generated by MPG and the LDC. IMD will undertake assay establishment, screening, hit identification and hit validation for LDC using its expertise and technology platform with the largest collection of pure natural products (NAT-PURER®) and fractionated extracts (PRE-FRACR®).
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.